Sanofi India Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/o7nf1rgkqoo33wk1gddgghfu.pdf

Key Takeaways


Business Model Transformation

Eric Mansion: "This year is pivotal for Sanofi India Limited, and we have completely transformed and modernized our business model with the aim to strengthen our leadership in the insulin market and to re-position ourselves with sustainable and profitable growth."

Export Reset

Rachid Ayari: "But despite the fact, what I can assure you the fact that this impact is significant in the top line, but in the bottom line, it is not because the export in terms of profitability versus the domestic... domestic segment."

OPEX & Margin Trajectory


Insulin Portfolio & Competitive Dynamics

Eric Mansion: "And considering the fact that biosimilar prices are equivalent to Lantus now after the NLEM of Lantus, the need for using biosimilars for the doctors is slowly, I would say, losing interest with Lantus available at the same price being an innovator."

Product Pipeline & Launch Caution

Rachid Ayari: "Now regarding certain products that we have in the portfolio at the global level in terms of price, I'm not sure that the Indian patient can offer such product."

AI & Digital

Eric Mansion: "We are really leveraging on AI wherever we can... we are really all in on AI, and we are trying to empower all Sanofian with the right tools in order to amplify the capabilities and make sure that we create value."

Guidance & Commitments

CommitmentSpecificsTimeline
Export recovery ceilingWill not cover 100% of lost export revenueOngoing
No new product launchesNo new products expected; business cases under validationCalendar 2026
OPEX trajectoryOPEX will not increase; optimization and efficiency sought year over yearOngoing
Personnel cost savingsSavings will increase quarter over quarter from the restructuringNext several quarters
Full-year comparabilityTransformation will be comparable apple-to-apple2026
Diabetes focusAccelerate Toujeo and Soliqua performance for at least 1.5 yearsAt least 1.5 years
Margin expansionExpecting improvement in OPEX ratio versus net sales if current trajectory holdsUpcoming years

Key Metrics

MetricQ2 FY26
Revenue from operations (sales)93% to 94% of total revenue
Diabetes insulin portfolio growth+5% quarter-to-quarter vs last year
Partnership portfolio growth+5% quarter-to-quarter
Exports as a share of total sales12% to 13%
OPEX (personnel and other) change-30% vs last quarter
OPEX ratio to sales22%
Export profit contribution~8% of total profit before tax
Profit before tax growth (Q3 vs Q3 2024)Double-digit growth
PBT to net sales ratio29%, improved from 23% in Q3 2024
Operating margin~28% this quarter
Interim dividend₹75 per share for YTD September
Employee costs~₹42 cr, down from ~₹56 cr last quarter
Exceptional item (VRS restructuring)₹27 cr booked in Q3
India revenue contribution81% of total revenue
Obsolescence rate~1%, improved from higher levels in the past